Clinical Trial Update: Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dexamethasone with or without oblimersen for relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Genasense (oblimersen) (oblimersen)

Snippet

Sponsor: Genta Incorporated | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 3 | Status: COMPLETED